Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome

Lambert-Eaton Myasthenic Syndrome

David Lacomis – Lambert-Eaton Myasthenic Syndrome Catalyst Pharmaceuticals, Inc. – Lambert-Eaton Myasthenic Syndrome Ricardo Maselli – Lambert-Eaton Myasthenic Syndrome Vern C. Juel, M.D. – Lambert-Eaton Myasthenic Syndrome Tessa L Marburger – Lambert-Eaton Myasthenic Syndrome University of Colorado, Denver – Lambert-Eaton Myasthenic Syndrome University of Pittsburgh – Lambert-Eaton Myasthenic Syndrome Catalyst Pharmaceutical Partners, Inc – Lambert-Eaton Myasthenic Syndrome The Cleveland Clinic – Lambert-Eaton Myasthenic Syndrome

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP Treatment of Lambert-Eaton Syndrome With 3,4 DAP 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)